Arrhythmias & electrophysiology
One-year outcomes after stereotactic body radiotherapy for refractory ventricular tachycardia
Authors' conclusion
For a select group of high-risk patients with VT refractory to standard therapy, SBRT is associated with a reduction in VT and appropriate ICD therapies over 1 year.
Study context
- Population
- Patients with ventricular tachycardia (VT) refractory to maximal medical and ablation therapy14 (93%) treated
- Participants
- 15 patients
- Exposure
- Stereotactic body radiotherapy (SBRT) vs 6 months before treatment
- SBRTn = 14
- Outcome
- VT burden (ICD shocks and antitachycardia pacing sequences), clinical and safety outcomes
- Follow-up
- 6 weeks, 6 months, and 12 months
Methodological detailssingle-group, before-after comparison
- Single-group
- Before-after comparison
Main finding
As reported in the abstract
Reduction in treated VT vs 6 months before treatment
Reduction in treated VT, 6 weeks to 6 months
98%
Reduction in treated VT, 12 months
99%
VT recurrence with appropriate ATP or ICD shocks, 6 weeks to 12 months
33%
4 of 12
Observational data: associations, not effects.
Further findings
Survival
- Surviving to end of 6-week period
- 12 (80%)
- Surviving to 12 months
- 10 (67%)
Amiodarone dose · 12 months
- Nonsignificant trend toward lower amiodarone dose
Deaths after treatment and ventricular function
- Deaths after treatment
- 4
- No changes in ventricular function
Original publication
One-year outcomes after stereotactic body radiotherapy for refractory ventricular tachycardia. Heart Rhythm. Published 11 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →